Hypercapnic acidosis affects in vitro lung infection response in a pathogen-specific manner

Area of Science:

• Pulmonary immunology
• Respiratory medicine
• Cellular biology

Background:

• Hypercapnic acidosis (HCA) is characteristic of acute hypercapnic respiratory failure, often linked to respiratory infections.
• The precise effects of HCA on lung injury and immune responses during infection are not fully understood.
• Research is needed to clarify HCA's specific impact on alveolar immune cell responses during lung infections.

Purpose of the Study:

• To investigate the impact of HCA on alveolar epithelial and macrophage responses during bacterial lung infections.
• To elucidate how HCA influences inflammatory signaling, barrier integrity, and bacterial survival in the lungs.
• To differentiate host responses to HCA in the context of different bacterial pathogens.

Main Methods:

• Developed an in vitro co-culture model with human alveolar epithelial cells (types I and II) and THP-1 macrophages.
• Infected cultures with Pseudomonas aeruginosa or Streptococcus pneumoniae under normocapnic or HCA conditions.
• Assessed inflammatory cytokine expression (IL-1β, CCL2, IL-8), tight junction protein levels (occludin, ZO-1), and bacterial survival at 1 and 24 hours post-infection.

Main Results:

• HCA modulated inflammation in a pathogen-specific manner; S. pneumoniae-induced IL-1β was CO2-driven, while P. aeruginosa induced IL-1β irrespective of CO2.
• Tight junction proteins were upregulated at 1 hour under HCA, especially with macrophages, but occludin decreased at 24 hours, suggesting impaired epithelial repair.
• Extracellular bacterial loads were unaffected by CO2, but HCA promoted intracellular P. aeruginosa replication in macrophages.

Conclusions:

• HCA differentially influences host responses based on the infectious pathogen.
• HCA compromises pulmonary barrier function and prolongs lung inflammation, potentially aiding bacterial persistence.
• Understanding these pathogen-specific effects of HCA is crucial for managing respiratory infections and lung injury.